An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ambrx Biopharma Inc. to Participate in the Cowen 42nd Annual Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Ambrx Biopharma Inc. (NYSE: AMAM) announced participation by Dr. Feng Tian, Chairman, President, and CEO, at the Cowen 42nd Annual Health Care Conference from March 7-9, 2022. Dr. Tian will join a corporate panel discussion on ‘Breast Cancer’ on March 9 at 2:10 p.m. Eastern Time. Interested investors can access the live webcast via the company's website, with a replay available for 30 days post-event. Ambrx focuses on developing Engineered Precision Biologics, including next-generation therapies for various diseases.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx, will participate in the Cowen 42nd Annual Health Care Conference taking place March 7-9, 2022.
Dr. Tian is scheduled to participate in the ‘Breast Cancer’ corporate panel discussion on Wednesday, March 9, at 2:10 p.m. Eastern Time.
Interested parties can access the live webcast for this conference from the Investor Relations section of the company's website at www.ambrx.com. The webcast replay will be available after the conclusion of the panel discussion for approximately 30 days.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com.
